Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Open-Label Study of the Efficacy of ABT-199 (GDC-0199) in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia Harboring the 17p Deletion

X
Trial Profile

A Phase 2 Open-Label Study of the Efficacy of ABT-199 (GDC-0199) in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia Harboring the 17p Deletion

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 16 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Venetoclax (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 17 Jun 2022 Results of final analyses after 5 y from last patients enrolled, including post-hoc subgroup analyses of prognostic markers presented at the 27th Congress of the European Haematology Association
    • 08 Dec 2020 Results (n=1138) of a retrospective analysis assessing rates of tumor lysis syndrome and outcomes and data were pooled from eight clinical studies: M15-550, M15-889, CLL14, M16-778, M14-032, M13-982, M14-728 and MURANO presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
    • 24 Nov 2020 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top